Fox Chase Researchers Find Novel Histone-Dependent PARP-1 Inhibitors More Effective at Treating Prostate and Renal Cancers
PHILADELPHIA (August 31, 2020)—In a recent study, researchers at Fox Chase Cancer Center identified agents that can specifically target the histone-dependent route of PARP-1 activation. This novel approach appears to be able to target cancer cells better than traditional NAD-like PARP-1 inhibitors and could have potential for developing new treatments for urologic tumors.